TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04611828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips SmartSleep
Description: closed-loop auditory stimulation
Study: NCT01882504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab
Study: NCT02389400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Single Group Assignment
Study: NCT01833572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Eligible participants will be given orally gefitinib 250mg daily before surgery for 42 days or until disease progression or unacceptable toxicity. Best supportive care is allowed in this period.
Study: NCT03676140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole on Day 1
Description: Albendazole 400 mg oral tablet Single Dose Treatment on D1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole on Day 1
Description: Albendazole 400 mg oral tablet Single Dose Treatment on D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin on Day 1
Description: Ivermectin 200 µg/kg oral tablet Single Dose Treatment on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin on Day 1
Description: Ivermectin 200 µg/kg oral tablet Single Dose Treatment on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine on day 1
Description: Diethylcarbamazine 6 mg/kg oral tablet Single Dose Treatment on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diethylcarbamazine on day 1
Description: Diethylcarbamazine 6 mg/kg oral tablet Single Dose Treatment on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin on Day 1
Description: Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin on Day 8
Description: Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 8
Study: NCT04375514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-ENaC
Description: single or multiple doses of ARO-ENaC by inhalation of nebulized solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: calculated volume to match active treatment by inhalation of nebulized solution
Study: NCT02464410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational intervention
Description: The intervention session combines elements of motivational enhancement (ME) and cognitive behavioral therapy (CBT). Similar to other ME brief interventions, the intervention content will be covered in a single session. Participants are presented with a variety of risk reduction strategies and strategies for coping with pain that may reduce reliance on opioids for managing pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-educational control
Description: The educational control condition provides educational content related to the biology of pain response and an overview of pain conditions. The overall style is didactic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Long-term opioid therapy informed consent
Description: The Veterans Health Administration instituted a requirement that all patients receiving long-term opioid therapy receive an informed consent process that reviews the risks of opioid therapy. All individuals eligible for this study will meet this definition of long-term opioid therapy. The study therapists for both study arms will deliver the informed consent process during the sessions as part of treatment as usual.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-term opioid therapy informed consent
Description: The Veterans Health Administration instituted a requirement that all patients receiving long-term opioid therapy receive an informed consent process that reviews the risks of opioid therapy. All individuals eligible for this study will meet this definition of long-term opioid therapy. The study therapists for both study arms will deliver the informed consent process during the sessions as part of treatment as usual.
Study: NCT04182672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006
Description: Subjects will be injected with the 5mL of FX006. This injection may be followed with up to 3mL of ropivacaine (depending on the capacity of the bursa), under ultrasound guidance.
Study: NCT03150420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Intravenous Sodium Thiosulfate Injection (25 grams sodium thiosulfate) to be administered each hemodialysis session (3 times weekly) for 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Normal Saline
Description: Placebo: to be administered each hemodialysis session (3 times weekly) for 3 weeks
Study: NCT02564809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit Brains Training
Description: These hourly classes will consist of cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individuals aim to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + Fit Brains Training
Description: These classes combine aerobic training and cognitive training. The classes will consist of a 15-minute walk prior to cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individual aims to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Balanced And Tone
Description: These classes will consist of hourly sham training class, hourly classes of sham exercise (e.g., balance, stretching, range of motion), and hourly educational classes.
Study: NCT00958646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulation
Description: Standardized rib raising protocol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Light touch control procedure
Study: NCT01665391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fresolimumab
Description: 1 mg/kg total body weight administered intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fresolimumab
Description: 4 mg/kg total body weight administered intravenous (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered to match active treatment group
Study: NCT00332228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: depot naltrexone
Description: long-acting depot parenteral formulation of naltrexone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: depot naltrexone
Description: long-acting depot parenteral formulation of naltrexone

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Compliance enhancement (CE)
Description: Compliance enhancement (CE), simulating standard treatment with oral naltrexone

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Compliance enhancement (CE)
Description: Compliance enhancement (CE), simulating standard treatment with oral naltrexone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT
Description: behavioral therapy with oral naltrexone maintenance for the treatment of heroin addiction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BNT
Description: behavioral therapy with oral naltrexone maintenance for the treatment of heroin addiction
Study: NCT03186417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 million hMSC/kg
Description: 2 million hMSCs/kg infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 million hMSC/kg
Description: 4 million hMSC/kg infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6 million hMSC/kg
Description: 6 million hMSC/kg infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo infusion
Study: NCT00837850

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone cement 1
Description: Bone cement SmartSet® HV

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone cement 2
Description: Bone cement Palacos R
Study: NCT00970229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I]MNI-420
Description: Subjects will be injected with 8mCi, not to exceed 8.8 mCi (not \> 10% of 8 mCi limit)of \[123I\]MNI-420, followed by SPECT imaging.
Study: NCT01129661

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL112 (reconstituted HDL)
Description: Single escalating intravenous doses of CSL112

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: normal saline (0.9%)
Description: Single intravenous dose of normal saline (0.9%)
Study: NCT02219074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sebacia microparticle and laser treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vehicle and laser treatment
Study: NCT02528786

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: No study drug will be administered in this study.
Study: NCT03274063

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supported self-management
Description: Participants will be supplied with urate self-testing kits. Participants will have a mobile phone application installed which will prompt the participant to perform urate self-testing, enable the clinical research team to advise on escalation of urate lowering therapy, and collect quality of life data .

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: Participants will have a mobile phone application installed which will allow the research team to collect quality of life data.
Study: NCT04356235

Intervention type: PROCEDURE
Intervention: A: expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction
Description: expander-silicone implant exchange and contralateral symmetrization with mastopexy and if needed with volume reduction

Intervention type: PROCEDURE
Intervention: B: expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling
Description: expander-silicone implant exchange with contralateral symmetrization with mastopexy and Ultrapro sling

Intervention type: PROCEDURE
Intervention: C: expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation
Description: expander-silicone implant exchange and contralateral symmetrization with mastopexy and silicone implant augmentation

Intervention type: PROCEDURE
Intervention: D: expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation
Description: expander-silicone implant exchange and contralateral symmetrization with mastopexy and Utrapro sling and silicone implant augmentation

Intervention type: PROCEDURE
Intervention: E: unilateral simple mastectomy
Description: unilateral simple mastectomy

Intervention type: PROCEDURE
Intervention: F: after bilateral SSM, ASM, NSM, expander-implant exchange
Description: after bilateral SSM, ASM, NSM, expander-implant exchange
Study: NCT04213716

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: silver nano particulate solution mixed with calcium hydroxide powder
Description: 1ml of nanosilver solution 30ppm concentration mixed with 100 mg of calcium hydroxide powder used as intracanal medication

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: conventional calcium hydroxide
Description: 1ml of distilled water mixed with 100 mg of calcium hydroxide powder and used as intracanal medication after root canal retreatment
Study: NCT02065505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mat Pilates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Pilates
Study: NCT03689816

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleeve gastrectomy
Description: sleeve gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric bypass
Description: gastric bypass
Study: NCT05312294

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu-M [inactivated split influenza vaccine] without preservative
Description: Solution for intramuscular injection, 0.5 ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu-M [inactivated split influenza vaccine] with preservative
Description: Solution for intramuscular injection, 0.5 ml
Study: NCT02223806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uterine Tonus Assessment by Midwife
Description: Uterine tonus assessment every 15 minutes for 2 hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient self-assessment of uterine tonus
Description: Uterine tonus assessment by patient every 15 minutes for 2 hours.
Study: NCT04072887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsules administered twice a day for 24 weeks
Study: NCT01540721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental paracetamol formulation
Description: Experimental formulation
Study: NCT00736840

Intervention type: DEVICE
Group type: OTHER
Intervention: c13 methacetin solution with breath analyzer
Description: Carbon 13 methacetin 75mg dissolved in 150 ml is given to the subject and metabolism is measured by a breath analyzer after decomposed by the liver
Study: NCT04102124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3680
Description: Tablet. Specifications of 80mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3680
Description: Tablet. Specifications of 80mg
Study: NCT02852096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual or Multiple Paraffin Blocks
Description: Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One Paraffin Blocks
Description: Assessing Her2/Neu Expression in Gastric Cancer With One Tumor Tissue Paraffin Blocks
Study: NCT02711423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Gantenerumab will be supplied as a high-concentration liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Gantenerumab will be supplied as a high-concentration liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as a matching liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
Study: NCT00843921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-carbamylglutamate
Description: 100 mg/kg/day or 2.2 g/M2/day in 3-4 divided doses for 3 days
Study: NCT04308317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrandrine
Description: Tetrandrine 60mg QD for 1week
Study: NCT00971347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extra sugar-free chewing gum sticks
Description: 90 minutes chewing per day after meals; mid-morning and mid-afternoon; 1 to 2 hours after dinner; and in response to hunger, cravings, preoccupation with eating, or negative feelings in general throughout the day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition brochure
Description: one-time at baseline visit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutrition brochure
Description: one-time at baseline visit
Study: NCT02018458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LA TNBC: DC vaccine+Preop chemo
Description: LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ER+/HER2-BC:DC vaccine+Preop chemo
Description: ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.
Study: NCT02493738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lozanoc 50mg
Description: Lozanoc 50mg single dose under fed and fasted condition
Study: NCT03563170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: NEXAVAR® tablets, for oral use

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin hydrochloride
Description: HCl

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
Study: NCT04102124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3162
Description: Tablet. Specifications of 10mg、40mg、50mg and 100mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR3680(Placebo)
Description: Tablet. Specifications of 80mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR3162(Placebo)
Description: Tablet. Specifications of 10mg、40mg、50mg and 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3162(Placebo)
Description: Tablet. Specifications of 10mg、40mg、50mg and 100mg
Study: NCT03190304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neprilysin
Description: To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
Study: NCT04072887

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: COPD maintenance background therapy
Description: Combination of fluticasone furoate, vilanterol and umeclidinium bromide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COPD maintenance background therapy
Description: Combination of fluticasone furoate, vilanterol and umeclidinium bromide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COPD maintenance background therapy
Description: Combination of fluticasone furoate, vilanterol and umeclidinium bromide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COPD maintenance background therapy
Description: Combination of fluticasone furoate, vilanterol and umeclidinium bromide
Study: NCT03190304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
Study: NCT03658031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin 10 mg administered each morning before breakfast
Study: NCT03749031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice + Orange Pomace
Description: 16 oz. orange juice + orange Pomace per day for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Orange Juice
Description: 16 oz. orange juice per day for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple Juice and Apple Pomace
Description: 16 oz. apple juice and apple Pomace per day for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apple Juice
Description: 16 oz. apple juice per day for 4 weeks
Study: NCT01466309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somnoguard oral appliances
Description: wearing somnogaurd daily at bedtime